NCT05114746 2026-03-16
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-03-02
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT06785636 2025-11-14
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT06516510 2025-09-25
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Blue Earth Therapeutics Ltd
Phase EARLY_PHASE1 Terminated
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed